A01 Characterization of NOTCH1 mutations in oral cavity squamous cell carcinomas. Kendrick Koo, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

A02 pRb-loss causes widespread changes to the transcriptome and proteome of cells. Wayne Miles, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

A03 FGF-WNT cooperativity and the role of IncRNAs in translational regulation in breast cancer. Tuan Nguyen, Baylor College of Medicine, Houston, TX, United States.


A05 An in vivo model reveals a role for Argonaute 2 in oncogenic KRAS driven pancreatic cancer initiation. Sunita Shankar, University of Michigan, Ann Arbor, MI, United States.

A06 Identification of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Tzu-Hao Wang, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

A07 MicroRNA-494 synergistically suppresses gastrointestinal stromal tumors by inhibition of KIT and Survivin, accompanying transcriptional and post-transcriptional inhibition of KIT. SeongJu Yun, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

A08 A 5' UTR RNA G-Quadruplex structure affects both the cap-dependent and independent translation of BAG-1, an mRNA involved in colorectal cancer. Rachel Jodoin, Université de Sherbrooke, Sherbrooke, QC, Canada.

A09 The role of pre-mRNA splicing factor in Glioblastoma Multiforme by regulating EGFRvIII. Young Taek Oh, National Cancer Center, Goyang-Si, Korea, Republic Of.

A10 Genome-wide mapping and subtype classification of long non-coding RNA in acute myeloid leukemia. Xiaoping Su, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A11 Profiling of miRNAs expression in pediatric brain tumors. Marwa Tantawy, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.

A12 Role of eIF5-mimic protein 1 (5MP1) for translational control in cancer. Katsura Asano, Kansas State University, Manhattan, KS, United States.

A13 eIF4a paralogue switching drives opposing phenotypes in cancer by specific reprogramming of gene expression. John Le Quesne, MRC Toxicology Unit, Leicester, United Kingdom.
A14 Proteomic analysis of paired malignant and non-malignant tissues from patients with NSCLC adenocarcinoma identified changes in translation initiation factors potentially important in oncogenesis. Suzanne Miyamoto, University of California, Davis Medical Center, Sacramento, CA, United States.

A15 Epigenetic up-regulation of ribosome biogenesis and more aggressive phenotype triggered by the lack of the histone demethylase JHDM1B in mammary epithelial cells. Lorenzo Montanaro, Bologna University, Bologna, Italy.

A16 A reconstituted cell-free translation system for the study of ribosome-mediated translational control in cancer. Marianna Penzo, University of Bologna, Bologna, Italy.

A17 Probing a translational switch involved in tumor angiogenesis. Maya Ramachandran, Columbia University, New York, NY, United States.

A18 microRNA-206 as a potential therapeutic approach for highly-associated NAFLD and HCC. Guisheng Song, University of Minnesota, Minneapolis, MN, United States.


A20 Baseline IL-17 receptor signaling is essential for controlling aberrant JNK-dependent cellular proliferation via maintenance of endogenous level of ubiquitin-editing enzyme A20. Chi Yan, Dalhousie University, Halifax, NS, Canada.

A21 mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Marie Cargnello, Lady Davis Institute/McGill University, Montreal, QC, Canada.

A22 Hypoxia-mediated translational control of hypoxia inducible factor 1 alpha through aldolase A feedback regulation in lung carcinogenesis. Yu-Chan Chang, Academia Sinica, Taipei, Taiwan.

A23 AMPK’s role in glioblastoma survival: An insight into its regulation on transcription factors and mTOR. Rishi Chhipa, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

A24 Translation control of tumor metastasis via FSTL1 binding with SPP1/OPN to modulated cytoskeleton remodeling. Jean Chiou, The Ph.D program for Cancer biology and drug discovery, China Medical University, Taichung, Taiwan.


A26 Heterogeneity in ribosomal RNA base modifications modulate lipid metabolic flux to maintain a tumor suppressive program. Adrian Contreras, University of California, San Francisco, San Francisco, CA, United States.

A28 Oxygen-dependent translatome remodeling is controlled by eIF2α dephosphorylation. J.J. Ho, University of Miami, Miami, FL, United States.


A30 Oncogenic MCT-1 activation deregulates oxidative metabolism and promotes lung tumor progression and metastasis. Hsin-Ling Hsu, National Health Research Institutes, Miao-Li, Taipei, Taiwan.

A31 eIF4F links translation to energy stress response in cancer. Laura Hulea, McGill University, Montreal, QC, Canada.

A32 The role of the ribosome in GCN2’s ability to sense amino acid deprivation and initiate the integrated stress response. Alison Inglis, MRC Laboratory of Molecular Biology, Cambridge, MA, United Kingdom.

A33 Understanding the functional role of enhanced FASN activity in regulating protein translation in DLCBL. Bandish Kapadia, University of Maryland, Baltimore, MD, United States.

A34 CELF1 is a central node in post-transcriptional regulatory programs underlying EMT and metastasis in breast epithelial cells. Arindam Chaudhury, Baylor College of Medicine, Houston, TX, United States.

A35 Drug repurposing for castration resistant prostate cancer based on disease-disease relationships. Gaurav Chopra, Purdue University, West Lafayette, IN, United States.

A36 A programmed ribosomal frameshifting defect potentiates the transforming activity of the JAK2-V617F mutation. Jonathan Dinman, University of Maryland, College Park, MD, United States.

A37 Blockade of ARV7:HIF1α heterodimers after toptoean reverses enzalutamide resistance in 22Rv1 cells. John Fruehauf, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA, United States.

A38 PTEN-mTOR pathway serves as a guardian of ribosomal DNA. Jennifer Gerton, Stowers Institute for Medical Research, Kansas City, MO, United States.

A39 Expression of DNA methylation-related proteins in metastatic breast cancer. YuKyung Lee, Department of Pathology, Yonsei University College of Medicine, Seoul, Korea, Republic Of.
A40 Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. YuKyung Lee, Department of Pathology, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

A41 Crosstalk between adipocytes and breast cancer promotes epithelial-mesenchymal transition. YuKyung Lee, Department of Pathology, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

A42 Role of cellular and extracellular Par-4 expression in tumor formation and drug sensitivity. Lourival Oliveira Filho, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.

A43 Comparative analysis of germline mutations of immune biomarkers pre- and post-HSCT in pediatric cancer patients. Pankita Pandya, Indiana University School of Medicine, Indianapolis, IN, United States.

A44 Diacetyl atractyloidol inhibits hypoxia-induced angiogenesis by suppressing the Akt-HIF-alpha signaling axis. Hyekyoung Shin, Department of surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic Of.

A45 Targeting eIF4A dependent translation as therapeutics in pancreatic cancer. Kamini Singh, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A46 Wnt5a signals through DVL1 to repress ribosomal DNA transcription by RNA polymerase I. Clara Vincent, Weill Cornell Medicine, New York, NY, United States.

A47 Immunogenic cancer cell death induced by high hydrostatic pressure and Hyperthermia: calreticulin exposure pathway. Sarka Vosahlikova, SOTIO, a.s., Prague, Czech Republic.

A48 Aberrant epigenetic regulation of GABRP is associated with an aggressive phenotype in ovarian cancer. Woong Ju, Ewha Womans University, Seoul, Korea, Republic Of.

A49 Transcription factor upregulation after mTOR inhibition by Torin1 induces growth factor receptor expression. Tianqing Yang, University of British Columbia, Vancouver, BC, Canada.
B01 SynMiCdb: The database for synonymous mutations in cancer identifies recurrent changes in conserved loci paralleling missense mutations. Karine Boulay, DKFZ, Heidelberg, Germany.

B02 A regulatory role for codon bias in KRAS-driven tumor progression and therapeutic resistance. Erin Kaltenbrun, Duke University, Durham, NC, United States.

B03 A whole genome screening platform to identify genes that overcome the poor translation of KRAS. Jackson Peterson, Duke University, Durham, NC, United States.

B04 Anti-HER2 therapies activate the PKR-elf2α serine 51 arm to promote tumor suppression in breast cancer. Antonis Koromilas, Lady Davis Institute-McGill University, Montreal, Quebec, Canada.

B05 Characterization of the pre-ribosomal complex, which mediates the p53 Impaired Ribosome Biogenesis Checkpoint (IRBC). Sandra Menoyo, Laboratory of Metabolism and Cancer, Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.

B06 Translational control of mitochondria through mTORC1/4E-BP signaling pathway. Masahiro Morita, McGill University, Montreal, QC, Canada.

B07 Loss of APC induces a dependence on elevated elf2B5 function in colorectal cancer. Stefanie Peter, University Hospital Wuerzburg, Wuerzburg, Germany.


B09 hnRNPA1 is a regulator of UNR IRES activity. Tobias Schmid, Institute of Biochemistry 1, Goethe-University, Frankfurt, Germany.

B10 Inhibiting eIF4F-mediated adaptive translatome reprogramming is a salvage strategy for targeted melanoma therapy. Shensi Shen, Gustave Roussy Cancer Campus, Villejuif, France.

B11 Oncogenic KRAS regulates 4E-BP1, a repressor of cap-dependent translation, independently of growth factor activity. Jillian Silva, University of California, San Francisco, San Francisco, CA, United States.

B12 Expression of Integrated Stress Response proteins during the progression of UVB-induced squamous cell carcinoma. Dan Spandau, Indiana University School of Medicine, Indianapolis, IN, United States.

B13 EGF/Ras/Erk signalling controls growth and proliferation through regulation of tRNA synthesis. Shrivani Sriskanthadevan-Pirahas, University of Calgary, Calgary, AB, Canada.

B14 Evidence that Tma20 and Tma22 do not promote translation re-initiation in yeast. Victoria Torrance, Newcastle University, Newcastle-Upon-Tyne, United Kingdom.
**Poster Session B**  
Saturday, October 29, 2016  
5:00 p.m.–7:00 p.m.  
Pacific A–G

B15 **Non-serine synthesis enzymatic function of phosphoserine aminotransferase 1 binds target proteins to promote metastatic progression in lung cancer.** Hsing-Fang Tsai, Genomics Research Center, Academia Sinica, Taipei, Taiwan.

B16 **Cytoplasmic RNA stress granules: A putative translational mechanism of mTOR regulation in glioblastoma.** Adrienne Weeks, Dalhousie University, Halifax, NS, Canada.

B17 **Precise statistical algorithms reveal novel fusions and potential impacts of fusions on translational regulation.** Julia Salzman, Stanford University Department of Biochemistry, Palo Alto, CA, United States.

B18 **Discovery of the mammalian ribo-interactome connects metabolism enzymes with specialized ER-ribosomes.** Deniz Simsek, Stanford University, Stanford, CA, United States.

B20 **Targeting eIF2α phosphorylation for cancer therapy.** Bertal Aktas, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

B21 **Novel pateamine A analogs to target pro-survival proteins in chronic lymphocytic leukemia.** Rong Chen, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B22 **Increased phosphorylation of eIF4E induces resistance to treatment with mTOR inhibitors together with AR antagonists in advanced prostate cancer.** Leandro D’Abronzo, University of California Davis, Davis, CA, United States.

B23 **Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer.** Luc Furic, Monash University, Clayton, Vic, Australia.

B24 **Development of a radiation modulator that functions via translation inhibition.** Nathan Gomes, University of Colorado / SuviCa Inc., Boulder, CO, United States.

B25 **Discovery of molecular probes inhibiting La:RNA interactions in cancer cells.** Tilman Heise, Medical University of South Carolina (MUSC), Charleston, SC, United States.

B26 **A novel naturally-derived withalongsidye synergizes with cisplatin to block self-renewal, migration, and EMT transition to enhance apoptosis via targeting of translational initiation.** Chitra Subramanian, University of Michigan, Ann Arbor, MI, United States.

B27 **Morphological changes, cadherin switching, and growth suppression in pancreatic cancer by GALNT6 knockdown.** Yunus Tarhan, University of Chicago, Chicago, IL, United States.

B28 **Discovery of 2-acetylpyridine-[N-(3-hydroxy-2-naphthoyl)]hydrazone analogs as glycine N-methyltransferase (GNMT) inducers for the treatment of hepatocellular carcinoma (HCC).** Cherng-Chyi Tzeng, Kaohsiung Medical University, Kaohsiung City, Taiwan.
B29 eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade. Kevin Webster, eFFECTOR Therapeutics, San Diego, CA, United States.

B30 The RNA-binding protein LARP1 is a cancer therapeutic target. Sarah Blagden, Department of Oncology, University of Oxford, Oxford, Oxfordshire, United Kingdom.

B31 NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Iok In Christine Chio, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.


B33 Translational control pathways form a molecular hub that regulates tamoxifen resistance in ER+ breast cancer. Phillip Geter, New York University School of Medicine, New York, NY, United States.

B34 Inhibitor of DNA binding (Id) regulates glioma infiltration on myelin tracts by suppressing Nogo receptor 1. JunHee Hong, Specific Organs Cancer Branch, National Cancer Center, Goyang-Si, Gyeonggi-Do, Korea, Republic Of.

B35 Defining changes in the cells' translation profiles in response to cancer therapies that target the ribosome. Eric Kusnadi, Peter MacCallum Cancer Center, Melbourne, Vic, Australia.

B36 Translational control of human colon tumor cell survival. Eyerusalem Lemma, University of Nebraska Medical Center, Omaha, NE, United States.

B37 Estrogen receptor alpha coordinates homeostatic gene expression programs via translational buffering. Julie Lorent, Karolinska Institute, Stockholm, Sweden.

B38 Tumor heterogeneity evaluation in glioblastomas using microarray of polysomal mRNAs. Fernanda Lupinacci, AC Camargo Cancer Center, Sao Paulo, Brazil.

B39 Asparagine drives translational adaptation of cancer cells to glutamine deficit. Natalya Pavlova, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B40 Intratumor heterogeneity in lung adenocarcinoma: Beyond genetics. Santiago RamonyCajal, Hospital University Vall’Hebron, Barcelona, Barcelona, Spain.

B41 Specific targeting of eIF4A mRNA helicase paralogs in lung cancer. Farheen Raza, Medical Research Council Toxicology Unit, Leicester, United Kingdom.

B42 Combination of liquid chromatography-surface enhanced Raman spectroscopy and liquid chromatography-mass spectrometry to identify SUMOylated proteins due to nutrient restriction in colorectal cancer. Monica Schroll, University of Notre Dame, Notre Dame, IN, United States.
Poster Session B  
Saturday, October 29, 2016  
5:00 p.m.–7:00 p.m.  
Pacific A–G

B43 Global upregulation of ribosomal protein gene pathway in normal cerebellar progenitor development and in pathogenesis of sonic hedgehog subtype medulloblastomas. Issei Shimada, UT Southwestern Medical Center, Dallas, TX, United States.

B44 Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells. Chara Stavraka, Imperial College, London, United Kingdom.

B45 Insights into the anti-prostate cancer activity of pterostilbene. Mai Tolba, Ain Shams University, Cairo, Non-Us/Non-Canadian, Egypt.

B46 Activation of TWIST1 by COL11A1 decreases cell sensitivity to paclitaxel by modulating NFκB-mediated IκB expression expression. Yi-Hui Wu, National Cheng Kung University, Tainan, Taiwan.

B47 A novel combination of Biochanin-A / 5-Fluorouracil against colon cancer: Impact on Wnt/beta-catenin signaling. Mai Tolba, Ain Shams University, Cairo, Egypt.

B48 Oncogenic Ras reprograms metabolism by suppressing TXNIP translation. Zhizhou Ye, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.